In individuals that lack a germline TP53 variant we identified alternative cancer-causing aberrations in 57.1% (8/14) of individuals with wildtype TP53 who developed cancer; this will enable the diagnosis of LFS in patients that would have been otherwise missed through standard screening procedures. Here, TP53 is linked to cancer.